We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+9.85%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.6B
AUM Growth
+$151M
Cap. Flow
-$15.9M
Cap. Flow %
-0.61%
Top 10 Hldgs %
41.87%
Holding
167
New
13
Increased
21
Reduced
24
Closed
25

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$27.5M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$23.6M
3
VTRS icon
Viatris
VTRS
+$18.4M
4
ABT icon
Abbott
ABT
+$18.2M
5
CVS icon
CVS Health
CVS
+$17.7M

Top Sells

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$20.5M
2
HCA icon
HCA Healthcare
HCA
+$18.3M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$15.9M
4
MDVN
MEDIVATION, INC.
MDVN
+$15.5M
5
STJ
St Jude Medical
STJ
+$12.4M

Sector Composition

Rank Sector Weight
1 Healthcare 91.79%
2 Real Estate 2.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
1
Gilead Sciences
GILD
$165B
$210M 8.09%
2,660,131
+148,400
+6% +$12.1M
CELG
2
DELISTED
Celgene Corp
CELG
$155M 5.97%
1,484,089
+85,300
+6% +$9.23M
BIIB icon
3
Biogen
BIIB
$30.9B
$151M 5.8%
482,033
+31,500
+7% +$9.33M
AGN
4
DELISTED
Allergan plc
AGN
$100M 3.84%
434,086
-29,800
-6% -$7.28M
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$93.6M 3.6%
764,005
+82,200
+12% +$10.6M
VRTX icon
6
Vertex Pharmaceuticals
VRTX
$123B
$90.1M 3.47%
1,033,503
– –
INCY icon
7
Incyte
INCY
$25.8B
$83M 3.19%
880,461
– –
MRK icon
8
Merck
MRK
$322B
$77.8M 2.99%
1,306,224
+470,342
+56% +$27.5M
BMRN icon
9
BioMarin Pharmaceuticals
BMRN
$11.9B
$65.7M 2.53%
710,145
+56,300
+9% +$5.3M
REGN icon
10
Regeneron Pharmaceuticals
REGN
$72.9B
$62M 2.38%
154,266
– –
ABT icon
11
Abbott
ABT
$187B
$58.3M 2.24%
1,378,600
+425,100
+45% +$18.2M
LLY icon
12
Eli Lilly
LLY
$1.08T
$57.3M 2.2%
713,767
+211,200
+42% +$16.9M
MDT icon
13
Medtronic
MDT
$112B
$53.8M 2.07%
623,030
-60,674
-9% -$5.29M
AMGN icon
14
Amgen
AMGN
$209B
$53.7M 2.06%
321,640
-10,100
-3% -$1.71M
UNH icon
15
UnitedHealth
UNH
$382B
$46.4M 1.78%
331,100
– –
SHPG
16
DELISTED
Shire pic
SHPG
$44.9M 1.73%
231,413
+29,700
+15% +$5.79M
ILMN icon
17
Illumina
ILMN
$29.5B
$44.8M 1.72%
253,464
-128,298
-34% -$20.5M
VTRS icon
18
Viatris
VTRS
$20.8B
$43.3M 1.66%
1,135,552
+413,000
+57% +$18.4M
JAZZ icon
19
Jazz Pharmaceuticals
JAZZ
$16.1B
$40.3M 1.55%
331,411
+174,960
+112% +$23.6M
JNJ icon
20
Johnson & Johnson
JNJ
$640B
$39.8M 1.53%
337,312
– –
PFE icon
21
Pfizer
PFE
$143B
$38.8M 1.49%
1,208,610
-354,779
-23% -$11.9M
CVS icon
22
CVS Health
CVS
$135B
$36.7M 1.41%
411,891
+188,000
+84% +$17.7M
TEVA icon
23
Teva Pharmaceuticals
TEVA
$40.4B
$36.3M 1.4%
788,958
+117,000
+17% +$6.1M
NBIX icon
24
Neurocrine Biosciences
NBIX
$18.2B
$33.3M 1.28%
656,622
-110,400
-14% -$5.5M
HUM icon
25
Humana
HUM
$43.9B
$29.2M 1.12%
164,800
+35,500
+27% +$6.16M
1
2 3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2016 Portfolio in Review

As of Q3 2016, Tekla Capital Management held 167 positions worth $2.6B, up 6.1% from $2.45B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Tekla Capital Management's Q3 2016 filing shows 13 new, 21 increased, 24 reduced and 25 closed positions. Its largest new stake was Cardinal Health: 152,500 shares worth $11.8M. The largest sale was Illumina, an estimated $20.5M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 86% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q3 2016 buy was Cardinal Health: 152,500 shares worth $11.8M.
  • Tekla Capital Management added most to Merck in Q3 2016, an estimated $27.5M increase.
  • Tekla Capital Management's biggest Q3 2016 reduction was Illumina, cutting an estimated $20.5M.
  • Tekla Capital Management fully exited State Street SPDR S&P Biotech ETF in Q3 2016, selling an estimated $15.9M.
  • Tekla Capital Management's ten largest holdings make up 42% of its $2.6B portfolio in Q3 2016.
  • Tekla Capital Management opened 13 new positions and closed 25 in Q3 2016.
  • Tekla Capital Management's portfolio value rose 6.1% quarter-over-quarter to $2.6B.

Based on Tekla Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.